Structure Therapeutics Inc. (GPCR) stock
GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.36−0.81 (-4.46%)
Close on Nov 18, 2026Market cap $1.24BP/E –Yield –
Structure Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Structure Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$257.81M. For fiscal 2025 it was -$176.56M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$176.56M | – |
| FY2024 | Dec 31, 2024 | -$158.23M | – |
| FY2023 | Dec 31, 2023 | -$102.78M | – |
| FY2022 | Dec 31, 2022 | -$52.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$118.63M | – |
| Q1 FY2026 | Mar 31, 2026 | -$89.38M | – |
| Q4 FY2025 | Dec 31, 2025 | $23.99M | – |
| Q3 FY2025 | Sep 30, 2025 | -$73.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$70.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$56.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$47.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$45.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.02M | – |
| Q4 FY2023 | Dec 31, 2023 | -$30.99M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.65M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.96M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.95M | – |
See a number that looks wrong?